Attending Companies Included | 참가 기업 포함
Developing Safe & Efficacious mRNA, CircRNA & SaRNA Medicines With Smarter Design Optimization, Targeted Delivery & Scalable Manufacturing for Clinical & Commercial Readiness
South Korea’s mRNA ecosystem is rapidly advancing, fueled by progress from companies like GC Biopharma and EyeGene in clinical-stage vaccines. Also, with the growing momentum of ARPA-H initiatives focused on personalized mRNA cancer therapies and strong government backing continues to drive the development of safer, more effective RNA-based medicines.
Amid this innovation, the World RNA-Based Therapeutics & Vaccines Summit returned to South Korea for its second year, highlighting breakthroughs in mRNA design, therapeutic pipelines, targeted delivery, and solutions to key manufacturing and analytical challenges. This was your chance to de-risk your program strategies, unlock insights from international leaders, and forge networks to develop better RNA medicines for patients faster.
As Korean RNA and vaccine companies strive to establish partnerships, out-license their assets, or create co-development collaborations with global companies, you could have joined 80+ mRNA therapeutic and vaccine developers to differentiate your technology and learnt how to generate meaningful data to open up the possibilities of future partnerships.
Supported by:
전문 연사 발표
Attending Companies Included
참가 기업 포함